Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2007
07/19/2007WO2007059356A3 Furfurylidene- pyrazolidines and their use as inhibitors of ubiquitin e1
07/19/2007WO2007058998A3 Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
07/19/2007WO2007058873A3 Imidazopyrazines as cyclin depentend kinase inhibitors
07/19/2007WO2007058338A3 Oxazole compound and pharmaceutical composition
07/19/2007WO2007056439A8 Salts of methylene blue and its derivatives
07/19/2007WO2007054453A3 Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa
07/19/2007WO2007053725A3 Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
07/19/2007WO2007053685A3 Methods of treating atrial fibrillation with p38 inhibitor compounds
07/19/2007WO2007048219A3 Sustained drug release composition
07/19/2007WO2007047406A3 Liquid pharmaceutical compositions of nimodipine
07/19/2007WO2007044435A3 Treatment of peripheral arterial occlusive disease
07/19/2007WO2007041052B1 Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
07/19/2007WO2007035722A3 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
07/19/2007WO2007035198A3 Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
07/19/2007WO2007025613A3 Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
07/19/2007WO2007022121A3 O-nitro compounds, pharmaceutical compositons thereof and uses thereof
07/19/2007WO2007017828A3 Oxazolidinone-quinolone hybrids as antibacterial compounds
07/19/2007WO2007016656A8 Modulators of hypoxia inducible factor-1 and related uses for the treatment of ocular disorders
07/19/2007WO2007016643A3 A method for extending longevity using npc1l1 antagonists
07/19/2007WO2007014673A3 Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation
07/19/2007WO2007012022A3 Unit dose form with ibuprofen-famotidine admixture
07/19/2007WO2007009083A3 Compounds with activity at retinoic acid receptors
07/19/2007WO2007007207A3 Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation
07/19/2007WO2006133835A3 Oral solid pharmaceutical formulation of the tubulin inhibitor indibulin
07/19/2007WO2006133523A3 Improved antimicrobial peroxidase compositions
07/19/2007WO2006131326A3 Novel use of (-)-epigallocatechin gallate
07/19/2007WO2006130553A3 Hcv protease inhibitors
07/19/2007WO2006125651A3 Ligustilide derivatives for the treatment of inflammatory disorders
07/19/2007WO2006113703A8 Carboline derivatives useful in the treatment of cancer
07/19/2007WO2006113431A3 Dual functional oligonucleotides for use as anti-viral agents
07/19/2007WO2006105372A3 Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
07/19/2007WO2006089067A3 Boron-containing small molecules
07/19/2007WO2006042751A3 Formulations containing alkylphosphocholines using novel negative charge carriers
07/19/2007WO2006037623A3 New nuclear transcription factors regulators
07/19/2007WO2006016828A8 Use of alpha ketoglutarate for treating alzheimer, parkinson
07/19/2007WO2006007310A3 Compositions of stable bioactive metabolites of docosahexaenoic (dha) and eicosapentaenoic (epa) acids
07/19/2007WO2005120546A3 Compositions and methods for topical diagnostic and therapeutic transport
07/19/2007WO2005072057A3 Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
07/19/2007WO2005033661A3 Dmbt1 as a clinical marker and uses thereof
07/19/2007US20070167630 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-Acetoxy-2-benzoyloxy-5,20-epoxy-1,13-dihydroxy-9,10-[(1S)-2-propenylidenedioxy]tax-6,11-diene; antitumor compounds; using low toxic and inexpensive materials; product is readily purified; industrial production
07/19/2007US20070167629 improved process from intermediate tert. butyl 3-(4-(5-ethyl-2-pyridyl)ethyloxy)phenyl-2-hydroxypropanoate; or starting reacting 4-phenoxybenzaldehyde and tert.butyl chloroacetate, epoxidation, decyclization, then reacting with 5-ethylpyridine-2-ethyl mesylate to form the intermediate
07/19/2007US20070167619 Novel uses of porphyrin compounds
07/19/2007US20070167530 Method for depletion of sulphur and/or compounds containing sulphur from a biochemically produced organic compound
07/19/2007US20070167529 Antimicrobial compositions for treating fabrics and surfaces
07/19/2007US20070167528 Methods of treating hepatocellular carcinoma with denspm
07/19/2007US20070167527 Memantine for the normalization of visual acuity deficits
07/19/2007US20070167526 Topical mecamylamine formulations for ocular administration and uses thereof
07/19/2007US20070167525 Combinations of metformin and a meglitinide
07/19/2007US20070167524 Phenylhept-6-yne-acid-4-hydroxy-3-methoxylbenzylamide (phenylcapsaicin); use as microorganism repellent agents in paints and coatings, for marine installations and ships, but also for land-based structures; nontoxic
07/19/2007US20070167523 Mixing HCl with a nateglinide mixture formed by reacting trans-4-isopropylcyclohexylcarbonyl chloride with D-phenylalanine in acetone, H2O and KOH; adjusting temperature to 63-65 degrees C. and concentration of acetone 8-22 wt %, and cooling the second reaction mixture to precipitatate the crystals
07/19/2007US20070167522 Branched carboxylic acid compound and use thereof
07/19/2007US20070167521 Novel structural analogs of corosolic acid having anti-diabetic and anti-inflammatory properties
07/19/2007US20070167520 purification of unsaturated polyfatty acid to stabilize and prevent reaction and oxidation; use as health dietetics
07/19/2007US20070167519 Novel Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof
07/19/2007US20070167518 Anti-tussive and bronchodilator actions of Enaminone E121
07/19/2007US20070167517 Stabilized derivatives of ascorbic aicd
07/19/2007US20070167516 Methods of using l-butylphthalide for the prevention and treatment of cerebral ischemia disease
07/19/2007US20070167515 e.g. iodomethylene-dimethyl-dihydropyranone; novelty of the chemical structure and of the mechanism of action; alkylation aldehyde with methyl [bis(2,2,2-trifluoroethyl)phosphinoyl]acetate followed by cyclization
07/19/2007US20070167514 Cannabinoid derivatives, methods of making, and use thereof
07/19/2007US20070167513 Crystalline forms of duloxetine free base
07/19/2007US20070167512 Lipid metabolism improving agent
07/19/2007US20070167511 Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
07/19/2007US20070167510 Methods for inhibiting osteoclastogenesis
07/19/2007US20070167509 Use of phenserine and analogs to treat behavioral problems and improve trainability
07/19/2007US20070167507 4-Carbox pyrazole derivatives useful as anti-viral agents
07/19/2007US20070167506 Parasiticides of alpha-substituted 2-benzylimidazoles, e.g., 2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole;insecticides; mitacides; ticks and varroa mites; animals; livestock; nontoxic; selectivity for the octopaminergic receptor; pharmakinetics; speed of action; topical spreading; solubility
07/19/2007US20070167505 Substituted benzimidazoles and their use for inducing apoptosis
07/19/2007US20070167504 Viral hepatitis treatment
07/19/2007US20070167503 Substituted benzoxazoles as estrogenic agents
07/19/2007US20070167502 Association between a heterocyclic compound and an antioxidant agent
07/19/2007US20070167501 Bicyclo derivative
07/19/2007US20070167500 Remedy for urinary tract diseases
07/19/2007US20070167499 Biaryl linked hydroxamates: preparation and pharmaceutical applications
07/19/2007US20070167498 Carboxylic acid compounds
07/19/2007US20070167497 such as N-(3,4-difluorobenzyl)-2-{[(5-methoxypyridin-3-yl)amino]sulfonyl}benzamide, having a cytochrome P450 monooxygenase enzyme system inhibitory activity, capable of increasing the bioavailability or improving the pharmacokinetics of coadministered drugs
07/19/2007US20070167496 Roflumilast and glycopyrronium combination
07/19/2007US20070167495 Pleuromutilin derivatives, process for their preparation and uses thereof
07/19/2007US20070167494 Process for preparing a polymorph or rosiglitazone maleate
07/19/2007US20070167493 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof
07/19/2007US20070167490 Imino ether derivative compounds and drugs containing the compounds as the active ingredient
07/19/2007US20070167489 Combination comprising antimuscarinic agents and PDE4 inhibitors
07/19/2007US20070167488 Novel therapeutic use
07/19/2007US20070167487 Novel alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
07/19/2007US20070167486 such as 3-[1-(2,4-Dimethoxybenzyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-N-hydroxypropionamide, used for preventing and treating the inflammatory diseases, for example rheumatoid arthritis, gout, osteoarthritis, lupus, arthritis, Crohn's disease, diabetes, bursitis, burns and scaring
07/19/2007US20070167485 N-benzyl-4-{[(1R)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide; phosphodiesterase inhibitor; antiinflammatory, antiallergenic agent; chronic obstructive pulmonary disease (COPD), asthma, or rhinitis
07/19/2007US20070167484 6-Alkoxy-pyrido-pyrimidines
07/19/2007US20070167483 Phenylalanine Enamide Derivatives
07/19/2007US20070167482 Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors
07/19/2007US20070167481 Imidazonaphthyridines
07/19/2007US20070167480 Pure and stable tiotropium bromide
07/19/2007US20070167479 Immune response modifier formulations and methods
07/19/2007US20070167478 Biomarkers for sensitivity of proliferative diseases to mtor inhibitors
07/19/2007US20070167477 Processes to prepare finasteride polymorphs
07/19/2007US20070167476 Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
07/19/2007US20070167475 Novel Processes for the Production of Useful Intermediates
07/19/2007US20070167474 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
07/19/2007US20070167473 Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
07/19/2007US20070167472 2-Methoxy-ethanesulfamic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide; vasoconstrictor, mediator of cardiac, renal, endocrine functions; neurotransmitter release, activation of inflammatory cells, fibrosis, cell proliferation and differentiation
07/19/2007US20070167471 Substituted quinazoline compounds useful as p38 kinase inhibitors
07/19/2007US20070167470 Spiro compounds and methods of use